Drugs / YY2201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06976931 | May 2025 → Apr 2027 expected | cancer | Jiangsu YaYao Biotechnology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YY2201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06976931 ↗ |
| Route | Oral | “receive multiple doses of YY2201 orally twice daily” NCT06976931 ↗ |